DexCom Inc
DXCM· Nasdaq
DXCMDexCom Inc
Filed Feb 9, 2023 · 10-K · 40 days after period end · 0001093557-23-000024
derived · Computed from the longer spans the company filed.
| Metric | Q4 2022dderived from reported figures | Q4 2021dderived from reported figures | Q4 2020dderived from reported figures | Q4 2019 |
|---|---|---|---|---|
| Revenue | $815.20M | $698.20M | $568.90M | $462.80M |
| Net Income | $91.80M | -$5.30M | $411.30M | $92.70M |
| EPS Diluted | — | — |
DexCom Inc · CIK 1093557 · Engraved from SEC EDGAR
| — |
| $1.00 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
ended Dec 31, 2022 · filed Feb 9, 2023 · 40 d after period end
